RenovoRx, Inc.
RenovoRx is a U.S. life sciences company commercializing the FDA-cleared RenovoCath device and developing its TAMP targeted chemotherapy delivery platform for solid tumors.
Last updated September 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
RenovoRx, Inc. is a United States-based life sciences company focused on targeted oncology. According to its own materials, the company develops innovative targeted oncology therapies and commercializes RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, aimed at high unmet medical needs. Its stated mission is to transform the lives of cancer patients by enabling targeted delivery of diagnostic and therapeutic agents. The company's core technology is its patented Trans-Arterial Micro-Perfusion (TAMP™) platform. TAMP uses the RenovoCath device to deliver chemotherapy directly near the tumor site, in contrast to conventional intravenous (IV) chemotherapy, which circulates the drug through the bloodstream and exposes the entire body. RenovoRx positions TAMP as a way to concentrate the chemotherapy drug near the tumor, potentially maximizing local drug exposure while reducing the systemic toxicities often seen with IV chemotherapy. The company highlights potential benefits including targeted delivery, improved tolerability, and the potential for patients to get back to normal activities that may have been limited during IV chemotherapy. RenovoRx states that TAMP may be incorporated at any point in an overall cancer treatment plan and is being explored for solid tumors such as pancreatic, lung, and sarcoma. The company has reported clinical and commercial milestones, including a Phase III TIGeR-PaC trial for locally advanced pancreatic cancer reaching full enrollment, first commercial clinical use of RenovoCath in a sarcoma patient, and record quarterly results driven by accelerating commercial adoption. RenovoRx is headquartered in Mountain View, California, and its CEO is Shaun R. Bagai, who has served as Chief Executive Officer and director since June 2014.
History
RenovoRx, Inc. is a life sciences company headquartered in Mountain View, California, in the United States. Public information about the company's earliest founding is limited in the supplied evidence; its leadership page states that Shaun R. Bagai has served as Chief Executive Officer and director since June 2014, providing an anchor for the company's modern leadership era. The company's development has centered on a targeted drug-delivery approach for oncology. RenovoRx describes itself as developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs. Its patented Trans-Arterial Micro-Perfusion (TAMP™) platform, utilizing RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor locally, while potentially minimizing a therapy's toxicities versus systemic intravenous chemotherapy. RenovoRx contrasts its approach with conventional intravenous (IV) chemotherapy, which circulates chemotherapy through the bloodstream and exposes the entire body to the drug. By contrast, TAMP delivers chemotherapy directly near the tumor, limiting total body exposure. The company lists potential TAMP benefits including targeted delivery, improved tolerability, and the potential for patients to get back to normal activities that may have been limited during IV chemotherapy. RenovoRx states that TAMP may be incorporated at any point in the overall cancer treatment plan and is being explored for solid tumors such as pancreatic, lung, and sarcoma. In its clinical and commercial progress, RenovoRx has reported several milestones. The company announced full enrollment in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, describing it as a major milestone. It also announced the first commercial clinical use of RenovoCath® in a sarcoma patient treatment, marking expansion of the targeted drug-delivery device to other solid tumors. In addition, RenovoRx reported record second quarter 2026 results, driven by accelerating commercial adoption and 61% sequential quarterly revenue growth. The company has also highlighted its TAMP™ platform at investor and key opinion leader events, such as a JonesTrading virtual key opinion leader event. RenovoRx's mission, as stated on its website, is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. The company continues to position TAMP and RenovoCath as a platform that may improve efficacy, safety, and tolerability in targeted oncology.
Shaun R. Bagai begins serving as Chief Executive Officer and director of RenovoRx.
RenovoRx announces full enrollment in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.
RenovoRx announces the first commercial clinical use of RenovoCath® in a sarcoma patient treatment.
RenovoRx reports record second quarter 2026 results with 61% sequential quarterly revenue growth.
Products and positioning
A life sciences company developing targeted oncology therapies and commercializing an FDA-cleared local drug-delivery device to enable targeted delivery of diagnostic and therapeutic agents near tumor sites.
RenovoCath®
A novel, FDA-cleared local drug-delivery device used to concentrate chemotherapy drug directly near the tumor.
TAMP™ (Trans-Arterial Micro-Perfusion)
A patented drug-delivery platform designed for targeted chemotherapy delivery across the arterial wall near the tumor site.
Recent events
RenovoRx prices initial public offering[5]
Reported:
RenovoRx announced the pricing of its initial public offering of 1,850,000 units at $9.00 per unit. The shares were expected to begin trading on Nasdaq on August 26, 2021, and the offering was expected to close on August 30, subject to customary closing conditions.
RenovoRx receives sixth U.S. patent[6]
Reported:
RenovoRx announced that the U.S. Patent and Trademark Office issued it a patent covering its Trans-Arterial Micro-Perfusion therapeutic method.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/renovorx-inc-united-states · Editorial policy · How profiles are compiled